-
www.ahrq.gov/hai/pfp/interimhac2014-ap1.html
November 01, 2015 - Saving Lives and Saving Money: Hospital-Acquired Conditions Update
Appendix: Incidence of Hospital-Acquired Conditions in the Partnership for Patients: Estimates and Projected and Measured Impact
Previous Page
Table of Contents
Saving Lives and Saving Money: Hospital-Acquired Conditions Update
…
-
www.ahrq.gov/research/findings/evidence-based-reports/search.html?page=42
February 01, 2001 - Evidence Reports Affiliation: McMaster University Report Status: Final
Prevention of Venous … Thromboembolism After Injury Report Type: Evidence Reports Affiliation: Southern California EPC—RAND
-
www.ahrq.gov/sites/default/files/wysiwyg/professionals/quality-patient-safety/patientsafetyculture/asc/ascwebinar/battlesslides.pdf
July 18, 2015 - is significant variability across
outpatient surgery facilities in the rates of (2015):
30-day venous … thromboembolism (0-3.4%)
30-day admission rates (0-7.7%)
30-day emergency department visits
-
www.ahrq.gov/sites/default/files/wysiwyg/npsd/Data_Submission_Dashboard_Data_2019.xlsx
January 01, 2019 - Healthcare-associated Infection CFER-H V1.1 1,557 0.6%
Healthcare-associated Infection CFER-H V1.2 8,653 1.0%
Venous … Thromboembolism CFER-H V1.2 201 0.0%
NOTE: Percentage sums to 100% within each 'Version'
-
www.ahrq.gov/news/newsroom/case-studies/ktcquips73.html
October 01, 2014 - and provider support calls for implementing the AHRQ-funded toolkit, Preventing Hospital-Acquired Venous … Thromboembolism: A Guide for Effective Quality Improvement . … recommended in the VTE toolkit. … daily monitoring of VTE risk assessment became amazingly clear. … to an increase in VTE prophylaxis orders.
-
www.ahrq.gov/news/newsroom/case-studies/ktcquips74.html
October 01, 2014 - and provider support calls for implementing the AHRQ-funded toolkit, Preventing Hospital-Acquired Venous … Thromboembolism: A Guide for Effective Quality Improvement . … Case studies revealed that one patient would have benefited from VTE prophylaxis." … the VTE toolkit. … protocol to be consistent with the VTE toolkit.
-
www.ahrq.gov/sites/default/files/publications2/files/interimhacrate2014_cx.pdf
November 19, 2015 - Saving Lives and Saving Money: Hospital-Acquired Conditions Update - Interim Data From National Efforts To Make Care Safer, 2010-2014
Saving Lives and Saving Money: Hospital-Acquired Conditions
Update
Interim Data From National Efforts To Make Care Safer, 2010-2014
Summary
Interim estimates for 2014 show a sust…
-
www.ahrq.gov/sites/default/files/publications/files/interimhacrate2014_2.pdf
November 19, 2015 - Saving Lives and Saving Money: Hospital-Acquired Conditions Update - Interim Data From National Efforts To Make Care Safer, 2010-2014
Saving Lives and Saving Money: Hospital-Acquired Conditions
Update
Interim Data From National Efforts To Make Care Safer, 2010-2014
Summary
Interim estimates for 2014 show a s…
-
www.ahrq.gov/research/findings/studies/index.html?page=110
January 01, 2024 - Among patients with AF but without acute venous thromboembolism, those who received an inappropriate … thromboembolism in US adults. … Patients with certain inflammatory skin diseases have multiple risk factors for venous thromboembolism … (VTE). … Association of inflammatory skin diseases with venous thromboembolism in US adults.
-
www.ahrq.gov/research/findings/evidence-based-reports/search.html?page=29
October 01, 2009 - Chapel Hill Report Status: Final
Outcomes of Genetic Testing in Adults with a History of Venous … Thromboembolism Date: June 2009
Report Type: Evidence Reports Affiliation: Johns Hopkins University
-
www.ahrq.gov/research/findings/studies/index.html?page=267
January 01, 2024 - Fleming KI , Agarwal J The impact of once- versus twice-daily enoxaparin prophylaxis on risk for venous … thromboembolism and clinically relevant bleeding. … This study compared pharmacodynamic and clinical outcomes, including 90-day venous thromboembolism and … thromboembolism risk reduction. … The impact of once- versus twice-daily enoxaparin prophylaxis on risk for venous thromboembolism and
-
www.ahrq.gov/hai/pfp/interimhac2013-ap1.html
December 01, 2014 - Efforts To Improve Patient Safety Result in 1.3 Million Fewer Patient Harms
Appendix
Previous Page Next Page
Table of Contents
Efforts To Improve Patient Safety Result in 1.3 Million Fewer Patient Harms
Appendix
References
Exhibit A1: 2013 Interim AHRQ National Scorecard Data o…
-
www.ahrq.gov/sites/default/files/wysiwyg/patient-safety/quality-measures/qsrs/qsrs-2021-2022-adverse-event-data-report.pdf
January 01, 2022 - Thromboembolism (VTE) 2.92.6
Other AEs 1.71.5
Blood or Blood Product 1.60.6
Birth – Maternal 0.0 … Venous
Thromboembolism (VTE)
Deep vein thrombosis (DVT) without pulmonary
embolism (PE)
PE without … Thromboembolism
(VTE)
7 3373 0.2 0.1 –
0.4
58 18276 0.3 0.3 –
0.4
Deep vein thrombosis
( … At Risk
AE
Rate
(%) 95% CI
Venous
Thromboembolism
(VTE)
29 11746 0.3 0.2 – 0.4 36 9903 0.4 … Thromboembolism
(VTE)
14 3719 0.4 0.2 –
0.6
55 21670 0.3 0.2 –
0.3
Deep vein
thrombosis
-
www.ahrq.gov/sites/default/files/wysiwyg/patient-safety/quality-measures/qsrs/qsrs-2021-2022-adverse-event-data-report-oct-rev.pdf
January 01, 2022 - Thromboembolism (VTE) 2.92.6
Other AEs 1.71.5
Blood or Blood Product 1.60.6
Birth – Maternal 0.0 … Venous
Thromboembolism (VTE)
Deep vein thrombosis (DVT) without pulmonary
embolism (PE)
PE without … Thromboembolism
(VTE)
7 3373 0.2 0.1 –
0.4
58 18276 0.3 0.3 –
0.4
Deep vein thrombosis
( … At Risk
AE
Rate
(%) 95% CI
Venous
Thromboembolism
(VTE)
29 11746 0.3 0.2 – 0.4 36 9903 0.4 … Thromboembolism
(VTE)
14 3719 0.4 0.2 –
0.6
55 21670 0.3 0.2 –
0.3
Deep vein
thrombosis
-
www.ahrq.gov/sites/default/files/wysiwyg/patient-safety/quality-measures/qsrs/qsrs-2021-2022-adverse-event-data-report-nov-rev.pdf
January 01, 2022 - Thromboembolism (VTE) 2.92.6
Other AEs 1.71.5
Blood or Blood Product 1.60.6
Birth – Maternal 0.0 … Venous
Thromboembolism (VTE)
Deep vein thrombosis (DVT) without pulmonary
embolism (PE)
PE without … Thromboembolism
(VTE)
7 3373 0.2 0.1 –
0.4
58 18276 0.3 0.3 –
0.4
Deep vein thrombosis
( … At Risk
AE
Rate
(%) 95% CI
Venous
Thromboembolism
(VTE)
29 11746 0.3 0.2 – 0.4 36 9903 0.4 … Thromboembolism
(VTE)
14 3719 0.4 0.2 –
0.6
55 21670 0.3 0.2 –
0.3
Deep vein
thrombosis
-
www.ahrq.gov/sites/default/files/wysiwyg/professionals/quality-patient-safety/pfp/updatedhacrateinfo.pdf
June 01, 2014 - 82,000 2.51 82,000 2.51
VAP MPSMS Ventilator-Associated
Pneumonia
35,000 1.07 34,000 1.02
VTE
-
www.ahrq.gov/research/findings/studies/index.html?page=463
January 01, 2024 - , Influenza
Ju MH , Chung JW , Kinnier CV Association between hospital imaging use and venous … thromboembolism events rates based on clinical data. … This study assessed the presence and extent of venous thromboembolism (VTE) surveillance bias using high-quality … have increased vigilance for VTE by performing more VTE imaging studies that result in higher VTE event … Association between hospital imaging use and venous thromboembolism events rates based on clinical data
-
www.ahrq.gov/sites/default/files/wysiwyg/npsd/Data_Submission_Dashboard_Data_2024.xlsx
January 01, 2024 - Healthcare-Associated Infection CFER-H V1.1 1,557 0.6%
Healthcare-Associated Infection CFER-H V1.2 17,405 0.7%
Venous … Thromboembolism CFER-H V1.2 247 0.0%
NOTE: Percentage sums to 100% within each 'Version'
-
www.ahrq.gov/sites/default/files/wysiwyg/professionals/quality-patient-safety/pfp/Updated-hacreportFInal2017data.pdf
July 01, 2020 - Infection
NHSN SSIs for 17 procedures w/CDC SCIP+5 data
VAP MPSMS Ventilator-Associated Pneumonia
VTE … 2.67
VAP MPSMS Ventilator-
Associated
35,894 1.21 27,548 0.93 25,695 0.86 31,213 1.05
Pneumonia
VTE … $22,898 0.026 (0.009–0.059) 0.028
VAP $47,238 ($21,890–$72,587) $22,898 0.140 (-0.110–0.730) 0.144
VTE
-
www.ahrq.gov/sites/default/files/2024-02/king-report.pdf
January 01, 2024 - Temporal trends in first-line
anticoagulation therapy for cancer-associated venous thromboembolism. … P5590 Temporal trends in
first line anticoagulation therapy for cancer-associated venous thromboembolism … P5239 Cost-effectiveness of direct oral anticoagulants for cancer-associated venous
thromboembolism.